Consolidated Q1 FY27 revenue rose to ₹6,972 million and net profit to ₹350.95 million, with EPS improving year-over-year. The Board approved new ESOP grants and completed an internal restructuring of overseas subsidiaries, with no material impact on financials.Original document: Rossari Biotech Ltd…
Consolidated Q1 FY27 revenue rose to ₹6,972 million and net profit to ₹350.95 million, with EPS improving year-over-year. The Board approved new ESOP grants and completed an internal restructuring of overseas subsidiaries, with no material impact on financials.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.